As a growing healthcare market, India is of strategic importance to Bio Products Laboratory (BPL), the specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, as the company continues to grow its global commercial presence there, and represents a business opportunity of up to £70M in the next 5 years.
Bio Products Laboratory: Support for strong trade links with India
BPL and Atlantic Research Group enter into long-term collaboration
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies headquartered in Elstree, UK, today announced the signing of a collaboration agreement with Atlantic Research Group (ARG), a global contract research organization (CRO) headquartered in Charlottesville, VA.
Bio Products Laboratory: £23m investment in new 1,000 square metres Filling and Sterilisation Facility at Elstree
Bio Products Laboratory (BPL), a specialist manufacturer of plasma-derived medicinal products, announces that it will be investing £23m to build a new Sterile Filling Suite at its Elstree site in the UK. From its base in Hertfordshire, BPL fractionates plasma to manufacture therapeutic products which are then supplied to patients in more than 45 countries around the world.
BPL sells 25 US plasma centres to Grifols for $370 million (£265 million)
Bio Products Laboratory (BPL) announces today the completion of a US$370 million (£265 million) transaction for the sale of 25 of its 51 US-based plasma centres to Biomat USA Inc, a subsidiary of Grifols S.A., a global healthcare company. Approximately 730 employees will be transferring to Biomat as part of the deal.
Government decision to remove ban on UK-sourced plasma
BPL welcomes the decision made by Government to lift the ban on UK plasma being used for the manufacture of immunoglobulins. BPL is very supportive of this Government initiative which will result in plasma from UK blood donors being used to manufacture life-saving medicines, and will help the UK become self-sufficient in plasma supply.
Bio Products Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Supply Immediately Available in the United States
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, today announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection, with supply immediately available.